00:14 , Feb 9, 2019 |  BioCentury  |  Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
01:53 , Feb 8, 2019 |  BC Week In Review  |  Company News

Via Merck KGaA Deal, GSK adds to growing immuno-oncology pipeline

Two months after announcing it would pay $5.1 billion for Tesaro Inc., GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has partnered with Merck KGaA (Xetra:MRK) in another deal to bolster its immuno-oncology pipeline. GSK is paying the German...
18:55 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Feb. 1, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I...
20:28 , Feb 6, 2019 |  BC Extra  |  Company News

Management tracks: Astellas, Blueprint

Astellas Pharma Inc. (Tokyo:4503) said President of Pharmaceutical Technology Mitsunori Matsuda and President of Asia & Oceania Business Masatoshi Kuroda will resign, effective June 18. Hideki Shima will succeed Matsuda. Cancer and rare diseases company...
23:39 , Feb 5, 2019 |  BC Extra  |  Company News

Via Merck KGaA deal, GSK adds to growing immuno-oncology pipeline

Two months after announcing it would pay $5.1 billion for Tesaro Inc., GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has partnered with Merck KGaA (Xetra:MRK) in another deal to bolster its immuno-oncology pipeline. GSK is paying the German...
23:18 , Feb 1, 2019 |  BioCentury  |  Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
01:14 , Jan 25, 2019 |  BC Week In Review  |  Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

In its latest move to build its gene editing capabilities, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in-licensed from Merck KGaA (Xetra:MRK) rights to two DNA damage response (DDR) inhibitors for gene editing applications. While Merck has been...
00:34 , Jan 25, 2019 |  BC Week In Review  |  Company News

Merck KGaA, Tencent to develop digital healthcare platforms for China

Merck KGaA (Xetra:MRK) partnered with Chinese internet giant Tencent Holdings Ltd. (HKSE:0700) to create intelligent digital healthcare service platforms to increase public knowledge of disease and treatment options within Merck's China healthcare business. The partnership...
22:22 , Jan 24, 2019 |  BC Extra  |  Company News

Merck KGaA, Tencent to develop digital healthcare platforms for China

Merck KGaA (Xetra:MRK) partnered with Chinese internet giant Tencent Holdings Ltd. (HKSE:0700) to create intelligent digital healthcare service platforms to increase public knowledge of disease and treatment options within Merck's China healthcare business. The partnership...
19:57 , Jan 24, 2019 |  BC Extra  |  Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

In its latest move to build its gene editing capabilities, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in-licensed from Merck KGaA (Xetra:MRK) rights to two DNA damage response (DDR) inhibitors for gene editing applications. While Merck has been...